NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024

NewAmsterdam Pharma Co N.V.

Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.
Revenue $29.1M in Q3 2024 from Menarini milestone; net loss $16.6M vs $47.1M in Q3 2023.
Phase 3 TANDEM topline data now expected in Q4 2024 due to faster enrollment.
On track for BROADWAY topline data in Q4 2024; BROOKLYN data at AHA Nov 16-18.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.